

ENCELIN OD 100/ TORGLIP OD 100

For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.

Abbreviated Prescribing information for ENCELIN OD 100/ TORGLIP OD 100
(Vildagliptin Sustained Release Tablets 100mg)

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

Mechanism of action: The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).

DOSAGE AND ADMINISTRATION: One tablet once daily or as directed by physician.

CONTRAINDICATION: Hypersensitivity to the active substance or to any of the excipients.

WARNINGS & PRECAUTIONS: Vildagliptin is not a substitute for insulin in insulin-requiring patients. Vildagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, Renal and Hepatic impairment, Liver enzyme monitoring, Cardiac failure, Skin disorders, Acute pancreatitis, Hypoglycaemia.

DRUG INTERACTION: Combination with pioglitazone, metformin and glyburide, Digoxin (Pgp substrate), warfarin (CYP2C9 substrate), with amlodipine, ramipril, valsartan or simvastatin with ACE-inhibitors.

ADVERSE REACTIONS: Hypoglycaemia, Tremor, Headache, Dizziness, Fatigue, Nausea, Nasopharyngitis, Asthenia, Constipation, Weight increase, Oedema peripheral, Upper respiratory tract infection, Arthralgia, Hyperhidrosis, chills, gastro-oesophageal reflux disease, flatulence, Pancreatitis, Hepatitis (reversible upon discontinuation of the medicinal product), Abnormal liver function tests (reversible upon discontinuation of the medicinal product), Myalgia, Urticaria, Exfoliative and bullous skin lesions, including bullous pemphigoid.

Marketed by:



IN/ENCELIN OD 100 /TORGLIP OD 100 mg/NOV-2021/01/ABPI

(Additional information is available on request)